AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, Université Paris Saclay, Inserm U 935, Villejuif, France.
AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, Université Paris Saclay, Inserm U 935, Villejuif, France; Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Surg Oncol. 2020 Jun;33:266-269. doi: 10.1016/j.suronc.2020.02.008. Epub 2020 Feb 15.
Even with the recent advances of surgical techniques and systemic therapies, we are often facing patients with multinodular bilateral disease for whom neither R0 nor R1 resection appears possible to perform. For such extensive cases, the tumor debulking approaches might provide a survival benefit, provided that an objective tumor response is obtained with chemotherapy. Here, we review all the arguments which may defend this strategy and propose some recommendations.
即使最近外科技术和系统治疗有了进展,我们仍经常面临双侧多结节性疾病患者,对这些患者而言,似乎不可能实现 R0 或 R1 切除。对于这种广泛的病例,肿瘤减积方法可能提供生存获益,只要化疗获得客观的肿瘤反应。在此,我们回顾了可能支持这一策略的所有论点,并提出了一些建议。